Key Highlights
- IDEXX Laboratories (NASDAQ:IDXX) reports third quarter 2026 results before the open on November 2, 2026; published consensus is EPS of USD 3.71 on Revenue of about USD 1.19 billion.
- Full-year 2026 EPS guidance was raised to USD 14.69 to USD 14.94 from USD 14.45 to USD 14.90, with revenue guided to USD 4.70 billion to USD 4.745 billion.
- US same-store clinic visits fell 1.3% in the second quarter and wellness visits fell 3.4%; management expects about a 1.5% visit decline in the second half.
- The recurring diagnostics organic growth target was raised to 9.5 to 10.7%, while instrument revenue fell 20% organically in the second quarter, per the company Q2 update.
What IDEXX Reports and the Bar
IDEXX Laboratories (NASDAQ:IDXX) is scheduled to report before the market opens on November 2, 2026. Published consensus is EPS of USD 3.71, with a higher whisper figure of USD 3.82, on revenue of about USD 1.19 billion. A year earlier the company earned USD 3.40 on USD 1.11 billion, so consensus implies roughly 9% EPS growth and 8% revenue growth, simple arithmetic on published numbers. Second quarter EPS was USD 4.27 on USD 1.22 billion. The full-year EPS range was raised even as consensus of USD 14.68 sat just below its low end, according to a published preview.
Fewer Visits, More Tests per Visit
IDEXX sells diagnostic tests and instruments to veterinary clinics, so its Recurring Revenue follows clinic traffic and testing intensity. When visits decline, growth must come from more tests per visit and price. The company has pointed to new products to do that: CancerDx has passed 10,000 ordering clinics and added mast cell tumor detection to a panel, InViewDX fine needle aspirate testing is expanding, and SDMA is now in chemistry profiles for North American customers. Management targets an Operating Margin improvement of 70 to 90 basis points, but a published preview notes little room if second-half Investment runs high, and instrument sales remain weak.
Risks, Valuation Context, and Dates
The key risk is that consumers cut elective pet spending, which would deepen the visit decline and slow testing. Instrument revenue fell 20% organically in the second quarter, though the DR50+ digital radiography system has posted six straight record quarters of placements. A currency headwind of USD 15 million is built into the outlook. Published data show the shares down about 7% since the last report and trading near USD 560, below the 200-day average of about USD 577. Marketwide, the S&P 500 fell 1.8% on October 30, 2026, while the stock lagged a flat index since its last report.
Where Things Stand
The diagnostics leader is IDEXX Laboratories (NASDAQ:IDXX), which raised its 2026 EPS outlook to USD 14.69 to USD 14.94 even as US clinic visits fell 1.3%. The two facts coexist because recurring diagnostics growth of 9.5 to 10.7% relies on more testing per visit, not more visits. The report before the open on November 2 will show whether that mix holds. Weak instruments, a second-half visit decline of about 1.5% and a share price below its 200-day average are the cautions.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...